Literature DB >> 17392601

Endogenous ghrelin increases in adriamycin-induced heart failure rats.

Z Xu1, W Wu, X Zhang, G Liu.   

Abstract

Evidence has indicated that plasma ghrelin was elevated in chronic heart failure (CHF) patients with cachexia. The present report studied whether pathophysiologic increment of endogenous ghrelin levels was existed in the progression of adriamycin (ADR)-induced CHF, then the possible compensatory mechanism by which the changes were induced and the relationship between active ghrelin, cardiac function and energy reserve in heart failure (HF) rats were explored. Cardiac function, high energy phosphates (HEP) content, and ghrelin levels in plasma and myocardium were measured at 4 days, 1, 2 and 3 weeks after the last injection of ADR, after which correlation analysis was performed between these markers in HF rats. Results showed that cardiac function decreased early, then was significantly restored and worsened at 3 weeks accompanied by the decrease of myocardial ATP content. Plasma ghrelin level increased significantly at each time point while myocardial ghrelin level increased transiently, then was restored followed by increased oxidative stress status and apoptosis in the weakening heart. Moreover, correlation analysis indicated that the markers of cardiac function and HEP were positively correlated to the endogenous ghrelin levels at the HF stage. This study indicated that the increase of endogenous ghrelin levels during the progression of the HF induced by ADR represent a compensatory self-protective effect by improving cardiac function and retaining myocardial energy reserve; this may be closely linked to anti-oxidative and anti-apoptosis mechanisms through regulating myocardial mitochondria function by ghrelin; but further investigations are necessary.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17392601     DOI: 10.1007/BF03347409

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  33 in total

1.  The impact of childhood cancer on the United States and the world.

Authors:  W A Bleyer
Journal:  CA Cancer J Clin       Date:  1990 Nov-Dec       Impact factor: 508.702

2.  Experimental myocardial ischemia characteristics of isolated mitochondrial subpopulations.

Authors:  R R Murfitt; J W Stiles; W J Powell; D R Sanadi
Journal:  J Mol Cell Cardiol       Date:  1978-02       Impact factor: 5.000

Review 3.  Cachexia in chronic heart failure: prognostic implications and novel therapeutic approaches.

Authors:  Yoshihiro J Akashi; Jochen Springer; Stefan D Anker
Journal:  Curr Heart Fail Rep       Date:  2005-12

Review 4.  Genetics of energetics: transcriptional responses in cardiac metabolism.

Authors:  H Taegtmeyer
Journal:  Ann Biomed Eng       Date:  2000-08       Impact factor: 3.934

5.  Postischemic recovery of contractile function is impaired in SOD2(+/-) but not SOD1(+/-) mouse hearts.

Authors:  Gregory K Asimakis; Scott Lick; Cam Patterson
Journal:  Circulation       Date:  2002-02-26       Impact factor: 29.690

6.  Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure.

Authors:  Noritoshi Nagaya; Junji Moriya; Yoshio Yasumura; Masaaki Uematsu; Fumiaki Ono; Wataru Shimizu; Kazuyuki Ueno; Masafumi Kitakaze; Kunio Miyatake; Kenji Kangawa
Journal:  Circulation       Date:  2004-11-29       Impact factor: 29.690

7.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach.

Authors:  M Kojima; H Hosoda; Y Date; M Nakazato; H Matsuo; K Kangawa
Journal:  Nature       Date:  1999-12-09       Impact factor: 49.962

8.  Ghrelin regulates mitochondrial-lipid metabolism gene expression and tissue fat distribution in liver and skeletal muscle.

Authors:  Rocco Barazzoni; Alessandra Bosutti; Marco Stebel; Maria Rosa Cattin; Elena Roder; Luca Visintin; Luigi Cattin; Gianni Biolo; Michela Zanetti; Gianfranco Guarnieri
Journal:  Am J Physiol Endocrinol Metab       Date:  2004-08-24       Impact factor: 4.310

9.  Mechanism of cardiac depression after trauma-hemorrhage: increased cardiomyocyte IL-6 and effect of sex steroids on IL-6 regulation and cardiac function.

Authors:  Shaolong Yang; Rui Zheng; Shunhua Hu; Yuchen Ma; Mashkoor A Choudhry; Joseph L Messina; Loring W Rue; Kirby I Bland; Irshad H Chaudry
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-11       Impact factor: 4.733

10.  Adriamycin stimulates low-affinity Ca2+ binding and lipid peroxidation but depresses myocardial function.

Authors:  P K Singal; G N Pierce
Journal:  Am J Physiol       Date:  1986-03
View more
  4 in total

1.  Ghrelin and cardiovascular diseases.

Authors:  Gaigai Zhang; Xinhua Yin; Yongfen Qi; Lakshmana Pendyala; Jack Chen; Dongming Hou; Chaoshu Tang
Journal:  Curr Cardiol Rev       Date:  2010-02

2.  Improvement of cardiomyocyte function by in vivo hexarelin treatment in streptozotocin-induced diabetic rats.

Authors:  Xinli Zhang; Linbing Qu; Ling Chen; Chen Chen
Journal:  Physiol Rep       Date:  2018-02

3.  A Linear Fragment of Unacylated Ghrelin (UAG6-13) Protects Against Myocardial Ischemia/Reperfusion Injury in Mice in a Growth Hormone Secretagogue Receptor-Independent Manner.

Authors:  David N Huynh; Hanan Elimam; Valérie L Bessi; Liliane Ménard; Yan Burelle; Riccarda Granata; André C Carpentier; Huy Ong; Sylvie Marleau
Journal:  Front Endocrinol (Lausanne)       Date:  2019-01-11       Impact factor: 5.555

4.  Ghrelin Receptor Agonist Rescues Excess Neonatal Mortality in a Prader-Willi Syndrome Mouse Model.

Authors:  Juan A Rodriguez; Emily C Bruggeman; Bharath K Mani; Sherri Osborne-Lawrence; Caleb C Lord; Henry F Roseman; Hannah L Viroslav; Prasanna Vijayaraghavan; Nathan P Metzger; Deepali Gupta; Kripa Shankar; Claudio Pietra; Chen Liu; Jeffrey M Zigman
Journal:  Endocrinology       Date:  2018-12-01       Impact factor: 4.736

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.